Last year, 2013, was a great year for myeloma research.

We had a number of important discoveries that will impact diagnosis, moni­tor­ing, prognosis, and treatment of the disease. Some new findings provide us with a better understanding of myeloma biology and mecha­nisms of drug resistance, while others present information that immedi­ate­ly impacts how patients are man­aged.

Collectively, these discoveries represent a significant advance to­wards our goal of curing myeloma.

I present here my list of the top 10 most compelling …

This “Manhattan Tale” is the first that I have written outside of Manhattan.

My wife and I are spending a few days in Washington, D.C., celebrating my brother-in-law’s 70th birthday. He and his wife live in Florida, and they have come up to DC for a chilly week to tour the sites of Washington, my hometown.

Just as the 20-degree cold we had a few nights ago gave a jolt to my brother-in-law and his wife, who are used to …

I have started 2014 in the throes of a relapse that has dogged my heels through­out the fall. When I see my oncologist this month, we will be dis­cussing treat­ment and, presumably, starting it soon thereafter.

Because the relapse is steadily increasing and my energy and overall health are steadily diminishing, we spent the holidays qui­et­ly. (Well, quietly after my hus­band finished five rehearsals and five performances in the space of three weeks.) When coworkers ask what I did for …

Hello, my name is Steve Mohr. I am 57 years old, and I was diagnosed with monoclonal gammopathy of undetermined significance (MGUS) in December of 2011, which was quickly revised to a diagnosis of multiple myeloma in April of 2012.

After reading this website almost daily since my initial diagnosis, I feel that, per­haps like every columnist who writes for The Beacon, I may be able to offer a helpful perspective to others with multiple myeloma, especially those newly diagnosed …

Findings from a recent retrospective study conducted at the Mayo Clinic show that certain newly diagnosed myeloma patients can achieve deep responses and long-term disease control through extended treatment with Revlimid and dex­a­meth­a­sone.

Among a large sample of patients who were initially treated with Revlimid and dex­a­meth­a­sone after diagnosis – and who did not undergo an early stem cell transplant – one fifth received the two-drug therapy for more than three years.

Almost two thirds of these patients who were treated for …

I recently had the opportunity to take a tour of the myeloma research laboratory at our local cancer center. During that tour, I got a close look at the latest myeloma research that is being done.

First, we were shown the DNA se­quenc­er. This is an expensive piece of equip­ment, paid for by generous donations. It cost about half a million dollars and is set up in a separate room to avoid any cross-con­tami­na­tion from other lab materials and people …

A medley of my local multiple myeloma buddies and I occasionally gather to­geth­er to shoot the breeze over mugs of high-priced coffee and an en­tic­ing as­sort­ment of sweet treats.

Accustomed to dietary restrictions, our klatch has determined that one of those delectable goodies is perfectly suitable for folks like us to consume -- in mod­er­a­tion, of course.

You see, way back when, some astute dessert engineers cleverly in­serted a large zero-calorie hole smack dab in the middle of said treat. …